Postpartum Hemorrhage (PPH) Treatment Devices Market

Postpartum Hemorrhage (PPH) Treatment Devices Market Analysis By Product (Uterine Balloon Tamponades, Non-pneumatic Anti-shock Garments & Uniject Prefilled Injection Systems) By End-User (Hospitals, Clinics & Others) By Region - Global Market Insights 2025 to 2035

Analysis of Postpartum Hemorrhage (PPH) Treatment Devices Market Covering 30+ Countries Icluding Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Postpartum Hemorrhage (PPH) Treatment Devices Market Outlook (2025 to 2035)

The postpartum hemorrhage treatment devices market size will be USD 998.2 million in 2025. According to Fact.MR analysis, the industry will expand with a CAGR of 5.7% and reach USD 1,740.6 million by the year 2035. The rising incidence of atonic uterus PPH, especially in developing countries, along with growing institutional deliveries, is one of the main drivers of growth.

Advances in technology in minimally invasive care and expanding access to gynecologic care are also fueling the need for efficient management tools for PPH. Postpartum hemorrhage remains a leading cause of maternal mortality, especially in low- and middle-income countries.

Though oxytocin and uterotonic medications have been the mainstay of early intervention for decades, expanding access to device-based interventions such as balloon tamponades, non-pneumatic anti-shock garments (NASG), and intrauterine vacuum-induced devices is radically altering treatment outcomes. They offer rapid, low-cost management of hemorrhage when drugs are not effective or unavailable. More government focus on maternal health, particularly through global health programs, is raising awareness and deployment of treatment for PPH.

Some of the key programs in Africa, South Asia, and Latin America are training skilled birth attendants and equipping healthcare facilities with PPH devices. At the same time, international collaborations are facilitating cost-subsidized procurement and public-private distribution arrangements to fill access gaps.

High-income economies, on the other hand, are experiencing increasing adoption of sophisticated electromechanical uterine tamponade systems. These are being employed within obstetric emergency protocols to limit dependence on surgical hysterectomy. Hospitals and maternity centers are adopting these solutions as part of maternal safety bundles in accordance with WHO and FIGO guidelines on early intervention. Rising litigation issues in obstetrics are also encouraging providers to embrace technologies with improved safety outcomes.

During the forecast period, the intersection of device miniaturization, telemedicine-driven interventions, and AI-driven risk prediction on obstetric wards will revolutionize PPH management. Developing technologies for early hemorrhage risk detection and automated blood loss tracking are gaining clinical traction, and pilot initiatives are already underway in major women's hospitals around the world. These developments should drive further commercialization and clinical implementation in the next decade.

Key Metrics

Metric Value
Estimated Global Size in 2025 USD 998.2 million
Projected Global Size in 2035 USD 1,740.6 million
CAGR (2025-2035) 5.7%

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Fact.MR Survey Results for Industry Dynamics Based on Stakeholder Perspectives

Fact.MR research on the postpartum hemorrhage treatment devices market indicates strong stakeholder decision dynamics. The top priority, as cited by 84% of obstetricians, is to reduce hemorrhage response time, where faster-application devices are favored over drug interventions.

Training and standardization, particularly for devices such as balloon tamponades and NASG, are of top priority, as cited by 77% of public hospital respondents. Costliness is still the determining factor in low-resource settings, with 72% of respondents pointing out the importance of cost-effective, reusable devices. Region by region, North America prioritizes EHR-integrated devices, Europe guideline harmonization, and Asia-Pacific low-cost access.

From a technology perspective, uptake is accelerating in AI-automated blood loss monitoring (61%), cutting-edge uterine balloon technologies (55%), and vacuum device portability to enhance mobile clinic accessibility (38%). Device scarcity and poor logistics persist, and 70% reference supply unpredictability, notably in rural areas. Delays due to African and Asian customs, as well as European and North American regulations, slow advancements.

Priorities for future investment are hemorrhage prediction models, simulation centers for maternity, and hybrid financial models. In the U.S., the EU, China, and India, publicized reforms are being adopted; policy changes to define standards and broaden access have become much more common. Enterprises should pay attention to compliance for long-term growth and investment in AI and blockchain, and they must make powerful partnerships with NGOs or health organizations to manage their training, infrastructure, and supply chain continuity.

Shifts in the Market from 2020 to 2024 and Future Trends 2025 to 2035

From 2020 to 2024, the Postpartum Hemorrhage Treatment Devices Market received more focus due to increased awareness of maternal health and the importance of emergency obstetric care. The increasing global maternal death complications led to increased utilization of PPH control interventions in developed and developing regions.

Uterine balloon tamponade systems, anti-shock pneumatic wraps, and oxytocin delivery systems saw increasing clinical use. Governments and NGOs assisted by emphasizing training and access to life-saving equipment in low-resource settings. Hospitals and clinics have invested in easy-to-operate, quick-acting machines for efficient complication management at delivery.

The industry is likely to change in 2025-2035 through expansion through enhanced technology and enhanced health infrastructure. Machines shall be more portable, low-cost, and stand-alone, reaching rural and developing countries. Smart monitoring systems integration will provide real-time monitoring of blood loss and vital signs for early detection and quick response.

Design for device reuse and sustainability, combined with greater remote training of healthcare professionals, will characterize the future. Joint efforts among healthcare providers and technology firms will also spur device design innovation in the area of proactive and scalable solutions for maternal care.

Comparative Market Shift Analysis (2020-2024 vs. 2025-2035)

2020-2024 2025-2035
Preferential first-line intervention with balloon tamponade and anti-shock clothing. Early detection and control automated smart-response systems.
Preferential improvement in access in low-resource settings by training and donations. Expansion of telehealth and mHealth technology integration.
Manual simple devices with limited functionality are used extensively in emergency obstetric care. Sensor-enabled intelligent devices with embedded data and automated response.
Preferential use by global health organizations in the developing world. Increased investment in scalable, locally manufactured PPH devices.
Limited awareness and acceptance among local providers in geographically isolated areas. Use of remote learning and virtual simulation for provider training.
Cost-effectiveness and quick deployment were top design considerations. Reusable, eco-friendly designs with enhanced patient monitoring.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Country-wise Analysis of the Postpartum Hemorrhage (PPH) Treatment Devices Market

Countries CAGR (%)
U.S. 6.9%
UK 5.8%
France 5.5%
Germany 5.3%
Italy 5.0%
South Korea 6.1%
Japan 5.6%
China 7.4%
Australia-NZ 5.9%

The U.S.

The U.S. postpartum hemorrhage treatment devices market will grow at 6.9% CAGR throughout the study period. Increasing awareness regarding maternal health and rising efforts to curb maternal mortality rates are strongly fueling the use of postpartum hemorrhage treatment devices among healthcare facilities. Hospitals and birthing centers are adopting standardized PPH management protocols that involve the use of intrauterine balloon tamponades, non-pneumatic anti-shock garments (NASGs), and surgical procedures.

Encouraging government policies, well-developed healthcare infrastructure, and access to skilled personnel allow for quicker uptake of PPH treatment technologies. The availability of prominent manufacturers of medical devices in the nation is also spurring innovation within the design and functionality of the treatment equipment and making them simpler to use both in an emergency as well as in regular obstetric practice.

Furthermore, increasing emphasis on training and simulation programs for obstetric emergencies ensures the effective deployment of PPH devices. As healthcare providers continue to prioritize maternal outcomes and safety, the U.S. is expected to remain a leading player in the postpartum hemorrhage treatment devices market over the next decade.

UK

UK's postpartum hemorrhage treatment devices market is expected to grow 5.8% CAGR in the analysis period. Growth due to growing instances of high-risk pregnancies, as well as an increased aged maternal populace, leads to increased recognition and readiness regarding control of complications occurring postpartum. Postpartum Hemorrhage still has a vast proportion of women undergoing maternal morbidity. Hence, doctors are raising concerns about making evidence-based protocols effective by inserting interventions with highly technological treatment apparatuses on time.

The use of intrauterine balloons, uterine compression devices, and pharmacological adjuncts in maternity units is becoming routine. Public health agencies and professional organizations are collaborating to facilitate structured training and emergency drills to enhance responsiveness. In addition, government investments in maternal and neonatal care services are strengthening the procurement and availability of critical PPH equipment. The UK postpartum hemorrhage treatment devices market can expect a steady expansion in PPH treatment devices from 2035.

France

The French postpartum hemorrhage treatment devices market will grow at 5.5% CAGR over the research period. The country's healthcare system is experiencing a slow escalation in the utilization of advanced PPH management tools due to an increased focus on maternal care and institutional delivery safety. Obstetric departments are increasingly taking a proactive role in treating hemorrhagic complications through end-to-end response strategies involving medical and device-based interventions.

The high incidence of cesarean deliveries and twin pregnancies is driving the clinical need for effective means of managing PPH. Regional health authorities are rolling out quality standards for postpartum care, stimulating the application of intrauterine tamponade devices and hemostatic drugs. Continuous training and professional education in hemorrhage control methods are preparing medical staff to handle emergencies effectively.

The incorporation of PPH devices within larger maternal health programs will help to enable the continued adoption and induce steady expansion of the French postpartum hemorrhage treatment devices market during the forecast period.

Germany

The German postpartum hemorrhage treatment devices market is anticipated to expand at 5.3% CAGR throughout the study. A highly organized healthcare system, along with a strong focus on maternal safety, is promoting the adoption of sophisticated treatment solutions for postpartum hemorrhage. Hospitals and maternity wards are increasingly outfitting labor and delivery rooms with emergency PPH kits containing intrauterine balloons, uterotonic medications, and rapid fluid resuscitation devices.

Regulatory backup for innovation in maternal healthcare equipment and increasing patient awareness of institutional birth safety are driving the adoption of technologically sophisticated products. Regular training of medical professionals and the inclusion of PPH equipment in clinical sim labs also enhance emergency response times.

With an increasing number of high-risk deliveries owing to age-related fertility and multiple births, the demand for successful and prompt control of hemorrhage is increasingly critical. Germany's established medical infrastructure and patient-centered policies are likely to drive consistent growth in the postpartum hemorrhage treatment devices market.

Italy

The Italian postpartum hemorrhage treatment devices market will grow at a 5.0% CAGR throughout research. Increasing focus on maternal standards of care and clinical safety while giving birth is propelling the growing use of postpartum hemorrhage treatment equipment in healthcare environments. While progress in implementation happens differently in city and rural establishments, country-level initiatives for uniform maternity care activities are starting to deliver positive gains.

Healthcare workers are increasingly being taught to use uterine tamponade systems, manual compression, and uterotonic administration for the management of PPH. Increased access to organized obstetric emergency response teams and education is promoting greater acceptance of life-saving devices in delivery room settings.

Public education campaigns emphasizing the dangers of postpartum complications are promoting institutional deliveries, which in turn provide support for deploying the right intervention tools. With ongoing support for the modernization of maternal care, Italy is likely to experience steady but incremental growth in the postpartum hemorrhage treatment devices market throughout the forecasting period.

South Korea

The South Korean postpartum hemorrhage treatment devices market is anticipated to expand at 6.1% CAGR throughout the study. An increased awareness of maternal health complications, along with high medical technology adoption, is driving demand for PPH treatment devices. Healthcare centers are focusing on readiness and swift intervention in labor and delivery wards through standardized PPH management procedures.

Government-driven maternal health improvement programs are complementing infrastructure development and access to emergency obstetric care equipment, such as uterine balloon tamponades and thermal management devices.

Domestic manufacturers provide low-cost, locally appropriate solutions that facilitate the adoption of advanced treatment devices. The integration of electronic monitoring systems and early-warning protocols also enhances clinical outcomes and minimizes maternal morbidity. With a strong resolve for medical progress and safety, South Korea is in a position to increase its presence in the worldwide postpartum hemorrhage treatment devices market.

Japan

The Japanese postpartum hemorrhage treatment devices market is anticipated to expand at 5.6% CAGR through the period of the study. Japan's aging population toward higher maternal age and rising cesarean section rates are generating greater awareness regarding complications like PPH.

Obstetric emergency guidelines in hospitals are being fortified with the incorporation of sophisticated PPH management tools and team preparedness through simulation-based training. The need for intrauterine tamponade devices, fluid resuscitation kits, and uterotonic drugs is on the increase as healthcare facilities embrace more evidence-based maternal care practices.

Technology-based innovations like minimally invasive hemorrhage control devices are also on the way into the clinical arena. With the backing of national health programs on preventing preventable maternal deaths, healthcare institutions are conforming to international best practices in the management of PPH. Japan's excellent level of maternal care and rigorous emphasis on clinical accuracy are likely to contribute to continued growth in the postpartum hemorrhage treatment devices market.

China

China is anticipated to have a 7.4% CAGR development in the course of the study. Growing maternal health infrastructure and heightened government attention to lowering maternal deaths are boosting a high rate of adoption of treatment devices for postpartum hemorrhage.

Increasing institutional delivery levels and enhanced provision of emergency obstetric care are allowing medical staff to respond quickly to cases of PPH. Government expenditure on rural healthcare and public health programs is widening the availability of crucial equipment like intrauterine balloons, NASGs, and blood transfusion kits.

Domestic producers are developing affordable and clinically approved PPH equipment that can cater to urban and rural hospitals' requirements. Training modules for midwives and obstetricians guarantee correct utilization and timely deployment. As China further enhances maternal health improvements through national planning and improved medical facilities, the postpartum hemorrhage treatment devices market is forecast to expand heavily and become a fundamental contributor to enhancing patient safety during delivery.

Australia-New Zealand

The Australia-New Zealand postpartum hemorrhage treatment devices market will grow at 5.9% CAGR throughout the study period. Robust healthcare systems and proactive efforts to improve maternal health outcomes are fueling the rising use of advanced postpartum hemorrhage treatment devices. Obstetric associations and hospital board guidelines suggest routine preparedness for postpartum hemorrhage across all delivery settings, resulting in large-scale implementation of emergency protocols.

Healthcare professionals are increasingly adding uterine tamponade devices, compression stockings, and fluid management sets to labor and delivery departments to manage hemorrhagic complications. Ongoing investments in maternal care training, simulation, and equipment upgrades are enhancing response capacity at both urban and rural healthcare facilities.

Increasing requirements for high-standard and standardized obstetric care, as well as support from governments in favor of perinatal safety programs, puts Australia and New Zealand as key targets for stable postpartum hemorrhage treatment device market growth within the forecast years.

Segment-wise Analysis

By Product Type

Uterine balloon tamponades were the leading segment by product type in the postpartum hemorrhage treatment devices market, with an industry share of 42.3%, followed by non-pneumatic anti-shock garments (NASGs) at 34.6%.

Uterine balloon tamponade (UBT) share holds the highest market share at 42.3%. It has functions that apply intrauterine pressure to maintain a safe and effective method of bleeding control. It is, therefore, minimally invasive and relatively cheap for treating PPH. Marketed systems include Bakri Balloon (Cook Medical), ESM-UBT (PATH), and Ellavi Balloon (Sinapi Biomedical) are being adopted internationally.

Therein, the increasing popularity of UBTs is evident with special reference to low- and middle-income countries (LMICs) affected by higher levels of maternal mortality. NGOs and international organizations like the WHO and UNFPA are continuously supporting the inclusion of UBT in maternal emergency kits. Additionally, research is underway for newer options utilizing biodegradable and self-inflating balloon designs for enhanced speed of deployment and ease of use in field settings.

The share of non-pneumatic anti-shock garments is 34.6%, and their increased use as first-response interventions particularly applies in rural or transport-delay settings. These garments, which are reusable and provide compression and stabilization to women in hypovolemic shock, are designed to assist with the directing of blood flow to the vital organs until definitive intervention is accessed. They are widely used across Sub-Saharan Africa and South Asia and are promoted by organizations such as Jhpiego and FIGO.

Zoex Corporation is providing these garments, often by partnering with government health programs. Given the fairly simple training needs and documented reduction in either mortality or morbidity incidence, NASGs are critical intervention tools in emergency obstetric care packages.

By End User

Projections for 2025 indicate that hospitals will occupy the largest share of the postpartum hemorrhage treatment devices market at 58.7%, while clinics will account for 27.5%. Hospitals thus lead the postpartum hemorrhage treatment devices market with 58.7% as they are primarily dedicated to high-risk deliveries and obstetric emergencies.

Usually, hospitals utilize a complete range of PPH treatment devices, balloon tamponades, electrosurgical devices, intrauterine hemostatic agents, and so forth in the context of tertiary and secondary care centers where cesarean sections and mass deliveries are the norm.

The major manufacturers, for example, Cook Medical, Becton Dickinson (BD), and Teleflex, manufacture and supply multi-purpose kits considered for use in hospitals, labor wards, and emergency obstetrics. Moreover, government-sponsored maternal health projects in Brazil, India, and China are increasingly focusing on ensuring that public hospitals implement a standard set of clinical protocols and devices for managing PPH, thereby reinforcing the dominance of this segment.

Clinics, 27.5% of the share, are an emerging area, particularly in regions with decentralized maternal care networks, such as Sub-Saharan Africa, Southeast Asia, and Latin America. These clinics are often first-contact providers for deliveries in peri-urban and rural areas where surgical access is limited. Cheap and user-friendly devices like non-pneumatic anti-shock garments (NASGs), Ellavi UBTs, and other hemostatic tools intended for field use seem to be gaining traction in clinics.

Meanwhile, humanitarian organizations such as PATH, FIGO, and USAID have been investing their resources to train midwives and clinic staff on the effective distribution of these devices in a bid to curb maternal mortality rates in settings outside a hospital. This increase in focus on task-shifting and decentralization is likely to drive the increased uptake of PPH devices in the clinical environment.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Competitive Outlook

The postpartum hemorrhage treatment devices market is dominated by innovation-driven competition, with large players concentrating on quick intervention, cost-effectiveness, and user-friendliness for resource-poor healthcare environments. The postpartum hemorrhage treatment devices market is moderately concentrated, with veteran medical device companies and nimble innovators competing to ramp up life-saving technology like balloon tamponade systems, non-pneumatic anti-shock garments (NASG), and advanced hemostatic agents.

Becton, Dickinson and Company (BD), Cook Medical, and Teleflex Incorporated are the leading companies, primarily due to their strong portfolios of surgical and obstetric devices designed to manage postpartum hemorrhage (PPH) with clinically proven instruments.

The acquisition of C.R. Bard by BD has further strengthened the company's position in women's health. Meanwhile, Cook Medical specializes in developing personalized obstetric kits for emergency treatment. Additionally, Utah Medical Products and Alydia Health have introduced new uterine tamponade and intrauterine balloon systems, with Alydia's Jada® system being particularly noted for its quick and minimally invasive approach.

Strategic approaches involve partnerships with maternal health NGOs, increased distribution in high-burden areas, and the inclusion of PPH devices within postnatal care guidelines. Investment is also placed on training modules and digital tools to support and enhance deployment in developed and emerging industries alike. The current scenario signals a firm dedication to decreasing maternal mortality via scalable, affordable and clinically effective solutions.

Market Share Analysis by Company

Company Name Market Share (%)
Becton, Dickinson and Company 22-26%
Cook Medical, Inc. 17-20%
Teleflex Incorporated 12-15%
Utah Medical Products, Inc. 9-12%
Alydia Health 7-10%
Other Players 17-33%

Key Company Insights

Becton, Dickinson and Company maintain a leading position in the postpartum hemorrhage treatment devices market, with an estimated 22-26% share in the industry. Its acquisition of C.R. Bard and Alydia Health has positioned BD as a frontrunner in clinically advanced solutions, including the highly regarded Jada® system. This platform's ability to provide rapid hemorrhage control in both hospital and low-resource environments reinforces BD’s strategic focus on scalable innovation as well as maternal health outcomes.

Cook Medical holds around 17-20% share, aided by its complete emergency obstetric kits designed for clinical readiness. Teleflex Incorporated, with a 12-15% share, extends its reach through procedural access and hemostatic product integration in obstetric environments. Utah Medical Products has 9-12%, aided by vacuum-based tamponade solutions as well as long-term provider relationships. Alydia Health, while now owned by BD, remains independently clinically significant with a revenue share of 7-10%, driven by its patented uterine control system widely used for its effectiveness in high-stakes environments.

Key Players

  • Becton, Dickinson and Company
  • Cook Medical, Inc.
  • Teleflex Incorporated
  • Utah Medical Products, Inc.
  • Alydia Health
  • 3RD Stone Design, Inc.
  • Revmedx Inc.
  • Bactiguard AB
  • C. R. Bard, Inc.

Segmentation

  • By Product

    • Uterine Balloon Tamponades
    • Non-pneumatic Anti-shock Garments (NASG)
    • Uniject Prefilled Injection Systems
  • By End User

    • Hospitals
    • Clinics
    • Others
  • By Region

    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia
    • Oceania
    • Middle East and Africa (MEA)

Table of Content

  • 1. Executive Summary
  • 2. Market Overview
  • 3. Key Market Trends
  • 4. Key Success Factors
  • 5. Market Background
  • 6. Global Market Volume (Units) Analysis 2020 to 2024 and Forecast, 2025 to 2035
  • 7. Global Market - Pricing Analysis
  • 8. Global Market Value Analysis 2020 to 2024 and Forecast, 2025 to 2035
  • 9. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Product
    • 9.1. Uterine Balloon Tamponades
    • 9.2. Non-pneumatic Anti-shock Garments (NASG)
    • 9.3. Uniject Prefilled Injection Systems
  • 10. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by End User
    • 10.1. Hospitals
    • 10.2. Clinics
    • 10.3. Others
  • 11. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Region
    • 11.1. North America
    • 11.2. Latin America
    • 11.3. Europe
    • 11.4. East Asia
    • 11.5. South Asia
    • 11.6. Oceania
    • 11.7. Middle East and Africa (MEA)
  • 12. North America Market Analysis 2020 to 2024 and Forecast 2025 to 2035
  • 13. Latin America Market Analysis 2020 to 2024 and Forecast 2025 to 2035
  • 14. Europe Market Analysis 2020 to 2024 and Forecast 2025 to 2035
  • 15. South Asia Market Analysis 2020 to 2024 and Forecast 2025 to 2035
  • 16. East Asia Market Analysis 2020 to 2024 and Forecast 2025 to 2035
  • 17. Oceania Market Analysis 2020 to 2024 and Forecast 2025 to 2035
  • 18. Middle East and Africa Market Analysis 2020 to 2024 and Forecast 2025 to 2035
  • 19. Key and Emerging Countries Market Analysis 2020 to 2024 and Forecast 2025 to 2035
  • 20. Market Structure Analysis
  • 21. Competition Analysis
    • 21.1. 3RD Stone Design, Inc.
    • 21.2. Bactiguard AB
    • 21.3. Becton, Dickinson, and Company
    • 21.4. C. R. Bard, Inc.
    • 21.5. Cook Medical, Inc.
    • 21.6. Alydia Health
    • 21.7. Revmedx Inc.
    • 21.8. Teleflex Incorporated
    • 21.9. Utah Medical Products, Inc.
  • 22. Assumptions and Acronyms Used
  • 23. Research Methodology

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2020 to 2035, By Product

Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By Product

Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By End User

Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By Region

Table 05: North America Market Value (US$ Mn) Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country

Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By Product

Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By End User

Table 08: Latin America Market Value (US$ Mn) Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country

Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By Product

Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By End User

Table 11: Europe Market Value (US$ Mn) Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country

Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By Product

Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By End User

Table 14: South Asia Market Value (US$ Mn) Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country

Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By Product

Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By End User

Table 17: East Asia Market Value (US$ Mn) Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country

Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By Product

Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By End User

Table 20: Oceania Market Value (US$ Mn) Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country

Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By Product

Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By End User

Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country

Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By Product

Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2020 to 2035, By End User

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Market Volume (in 000' Units) Analysis, 2020 to 2024

Figure 02: Global Market Volume Forecast (in 000' Units), 2025 to 2035

Figure 03: Pricing Analysis (US$) Per Product Type, By Region, 2024

Figure 04: Pricing Analysis (US$) Per Product Type, By Region, 2024

Figure 05: Global Market Value Analysis (US$ Mn), 2020 to 2024

Figure 06: Global Market Value Forecast (US$ Mn), 2025 to 2035

Figure 07: Global Market Absolute $ Opportunity, 2025 to 2035

Figure 08: Global Market Share Analysis (%), By Product, 2025 to 2035

Figure 09: Global Market Y-o-Y Analysis (%), By Product, 2025 to 2035

Figure 10: Global Market Attractiveness Analysis by Product, 2025 to 2035

Figure 11: Global Market Share Analysis (%), By End User, 2025 to 2035

Figure 12: Global Market Y-o-Y Analysis (%), By End User, 2025 to 2035

Figure 13: Global Market Attractiveness Analysis by End User, 2025 to 2035

Figure 14: Global Market Share Analysis (%), By Region, 2025 to 2035

Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2025 to 2035

Figure 16: Global Market Attractiveness Analysis by Region, 2025 to 2035

Figure 17: North America Market Value Share, By Product, 2025 (E)

Figure 18: North America Market Value Share, By End User, 2025 (E)

Figure 19: North America Market Value Share, By Country, 2025 (E)

Figure 20: North America Market Value Analysis (US$ Mn), 2020 to 2024

Figure 21: North America Market Value Forecast (US$ Mn), 2025 to 2035

Figure 22: North America Market Attractiveness Analysis by Product, 2025 to 2035

Figure 23: North America Market Attractiveness Analysis by End User, 2025 to 2035

Figure 24: North America Market Attractiveness Analysis by Country, 2025 to 2035

Figure 25: Latin America Market Value Share, By Product, 2025 (E)

Figure 26: Latin America Market Value Share, By End User, 2025 (E)

Figure 27: Latin America Market Value Share, By Country, 2025 (E)

Figure 28: Latin America Market Value Analysis (US$ Mn), 2020 to 2024

Figure 29: Latin America Market Value Forecast (US$ Mn), 2025 to 2035

Figure 30: Latin America Market Attractiveness Analysis by Product, 2025 to 2035

Figure 31: Latin America Market Attractiveness Analysis by End User, 2025 to 2035

Figure 32: Latin America Market Attractiveness Analysis by Country, 2025 to 2035

Figure 33: Europe Market Value Share, By Product, 2025 (E)

Figure 34: Europe Market Value Share, By End User, 2025 (E)

Figure 35: Europe Market Value Share, By Country, 2025 (E)

Figure 36: Europe Market Value Analysis (US$ Mn), 2020 to 2024

Figure 37: Europe Market Value Forecast (US$ Mn), 2025 to 2035

Figure 38: Europe Market Attractiveness Analysis by Product, 2025 to 2035

Figure 39: Europe Market Attractiveness Analysis by End User, 2025 to 2035

Figure 40: Europe Market Attractiveness Analysis by Country, 2025 to 2035

Figure 41: South Asia Market Value Share, By Product, 2025 (E)

Figure 42: South Asia Market Value Share, By End User, 2025 (E)

Figure 43: South Asia Market Value Share, By Country, 2025 (E)

Figure 44: South Asia Market Value Analysis (US$ Mn), 2020 to 2024

Figure 45: South Asia Market Value Forecast (US$ Mn), 2025 to 2035

Figure 46: South Asia Market Attractiveness Analysis by Product, 2025 to 2035

Figure 47: South Asia Market Attractiveness Analysis by End User, 2025 to 2035

Figure 48: South Asia Market Attractiveness Analysis by Country, 2025 to 2035

Figure 49: East Asia Market Value Share, By Product, 2025 (E)

Figure 50: East Asia Market Value Share, By End User, 2025 (E)

Figure 51: East Asia Market Value Share, By Country, 2025 (E)

Figure 52: East Asia Market Value Analysis (US$ Mn), 2020 to 2024

Figure 53: East Asia Market Value Forecast (US$ Mn), 2025 to 2035

Figure 54: East Asia Market Attractiveness Analysis by Product, 2025 to 2035

Figure 55: East Asia Market Attractiveness Analysis by End User, 2025 to 2035

Figure 56: East Asia Market Attractiveness Analysis by Country, 2025 to 2035

Figure 57: Oceania Market Value Share, By Product, 2025 (E)

Figure 58: Oceania Market Value Share, By End User, 2025 (E)

Figure 59: Oceania Market Value Share, By Country, 2025 (E)

Figure 60: Oceania Market Value Analysis (US$ Mn), 2020 to 2024

Figure 61: Oceania Market Value Forecast (US$ Mn), 2025 to 2035

Figure 62: Oceania Market Attractiveness Analysis by Product, 2025 to 2035

Figure 63: Oceania Market Attractiveness Analysis by End User, 2025 to 2035

Figure 64: Oceania Market Attractiveness Analysis by Country, 2025 to 2035

Figure 65: Middle East and Africa Market Value Share, By Product, 2025 (E)

Figure 66: Middle East and Africa Market Value Share, By End User, 2025 (E)

Figure 67: Middle East and Africa Market Value Share, By Country, 2025 (E)

Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2020 to 2024

Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2025 to 2035

Figure 70: Middle East and Africa Market Attractiveness Analysis by Product, 2025 to 2035

Figure 71: Middle East and Africa Market Attractiveness Analysis by End User, 2025 to 2035

Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2025 to 2035

Figure 73: U. S. Market Value Analysis (US$ Mn), 2025 & 2035

Figure 74: U. S. Market Value Share, By Product, 2025 (E)

Figure 75: U. S. Market Value Share, By End User, 2025 (E)

Figure 76: Canada Market Value Analysis (US$ Mn), 2025 & 2035

Figure 77: Canada Market Value Share, By Product, 2025 (E)

Figure 78: Canada Market Value Share, By End User, 2025 (E)

Figure 79: Mexico Market Value Analysis (US$ Mn), 2025 & 2035

Figure 80: Mexico Market Value Share, By Product, 2025 (E)

Figure 81: Mexico Market Value Share, By End User, 2025 (E)

Figure 82: Brazil Market Value Analysis (US$ Mn), 2025 & 2035

Figure 83: Brazil Market Value Share, By Product, 2025 (E)

Figure 84: Brazil Market Value Share, By End User, 2025 (E)

Figure 85: U. K. Market Value Analysis (US$ Mn), 2025 & 2035

Figure 86: U. K. Market Value Share, By Product, 2025 (E)

Figure 87: U. K. Market Value Share, By End User, 2025 (E)

Figure 88: Germany Market Value Analysis (US$ Mn), 2025 & 2035

Figure 89: Germany Market Value Share, By Product, 2025 (E)

Figure 90: Germany Market Value Share, By End User, 2025 (E)

Figure 91: France Market Value Analysis (US$ Mn), 2025 & 2035

Figure 92: France Market Value Share, By Product, 2025 (E)

Figure 93: France Market Value Share, By End User, 2025 (E)

Figure 94: Italy Market Value Analysis (US$ Mn), 2025 & 2035

Figure 95: Italy Market Value Share, By Product, 2025 (E)

Figure 96: Italy Market Value Share, By End User, 2025 (E)

Figure 97: Spain Market Value Analysis (US$ Mn), 2025 & 2035

Figure 98: Spain Market Value Share, By Product, 2025 (E)

Figure 99: Spain Market Value Share, By End User, 2025 (E)

Figure 100: Russia Market Value Analysis (US$ Mn), 2025 & 2035

Figure 101: Russia Market Value Share, By Product, 2025 (E)

Figure 102: Russia Market Value Share, By End User, 2025 (E)

Figure 103: China Market Value Analysis (US$ Mn), 2025 & 2035

Figure 104: China Market Value Share, By Product, 2025 (E)

Figure 105: China Market Value Share, By End User, 2025 (E)

Figure 106: Japan Market Value Analysis (US$ Mn), 2025 & 2035

Figure 107: Japan Market Value Share, By Product, 2025 (E)

Figure 108: Japan Market Value Share, By End User, 2025 (E)

Figure 109: South Korea Market Value Analysis (US$ Mn), 2025 & 2035

Figure 110: South Korea Market Value Share, By Product, 2025 (E)

Figure 111: South Korea Market Value Share, By End User, 2025 (E)

Figure 112: India Market Value Analysis (US$ Mn), 2025 & 2035

Figure 113: India Market Value Share, By Product, 2025 (E)

Figure 114: India Market Value Share, By End User, 2025 (E)

Figure 115: ASEAN Market Value Analysis (US$ Mn), 2025 & 2035

Figure 116: ASEAN Market Value Share, By Product, 2025 (E)

Figure 117: ASEAN Market Value Share, By End User, 2025 (E)

Figure 118: Australia Market Value Analysis (US$ Mn), 2025 & 2035

Figure 119: Australia Market Value Share, By Product, 2025 (E)

Figure 120: Australia Market Value Share, By End User, 2025 (E)

Figure 121: New Zealand Market Value Analysis (US$ Mn), 2025 & 2035

Figure 122: New Zealand Market Value Share, By Product, 2025 (E)

Figure 123: New Zealand Market Value Share, By End User, 2025 (E)

Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2025 & 2035

Figure 125: GCC Countries Market Value Share, By Product, 2025 (E)

Figure 126: GCC Countries Market Value Share, By End User, 2025 (E)

Figure 127: Turkey Market Value Analysis (US$ Mn), 2025 & 2035

Figure 128: Turkey Market Value Share, By Product, 2025 (E)

Figure 129: Turkey Market Value Share, By End User, 2025 (E)

Figure 130: South Africa Market Value Analysis (US$ Mn), 2025 & 2035

Figure 131: South Africa Market Value Share, By Product, 2025 (E)

Figure 132: South Africa Market Value Share, By End User, 2025 (E)

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

- FAQs -

How big is the postpartum hemorrhage treatment devices market?

The postpartum hemorrhage treatment devices market is estimated to reach USD 998.2 million by 2025.

What is the outlook on the sales of postpartum hemorrhage treatment devices in the market?

The postpartum hemorrhage treatment devices market is projected to grow to USD 1,740.6 million by 2035, driven by the increasing prevalence of postpartum hemorrhage, advancements in medical technologies, and the growing focus on maternal health.

Which country is showing notable growth in the postpartum hemorrhage treatment devices market?

China is expected to grow at a rate of 7.4% due to the expanding healthcare infrastructure and increasing awareness of maternal health issues.

Which product segment is leading the trend in postpartum hemorrhage treatment devices?

Uterine balloon tamponades are leading the trend in the postpartum hemorrhage treatment devices market, as they are an effective and widely used treatment for managing postpartum hemorrhage.

Who are the key players in the postpartum hemorrhage treatment devices market?

Key players in the postpartum hemorrhage treatment devices market include Becton, Dickinson and Company, Cook Medical, Inc., Teleflex Incorporated, Utah Medical Products, Inc., Alydia Health, 3RD Stone Design, Inc., Revmedx Inc., Bactiguard AB, and C. R. Bard, Inc.

Postpartum Hemorrhage (PPH) Treatment Devices Market

Schedule a Call